HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
First‑in‑human phase 1/2a study launches in China and the US targeting advanced cancers
Read More
Author: John Pinching
Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
New funding will support the phase 2 expansion trial of THEO-260
Read More
AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
DementAI prototype developed by Katalyze Data seeks to ease pressure on clinical teams
Read More
Quell launches chill phase 1/2 trial for novel cartreg therapy
Company targets new approach to treating rheumatoid arthritis and systemic sclerosis
Read More
Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
Early data show faster viral clearance and favourable safety in mild to moderate COVID‑19
Read More- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
